These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2605013)

  • 1. Neuroendocrine challenges in the diagnosis of depressive disorders.
    López-Ibor JJ; Saiz-Ruiz J; Moral Iglesias L
    Br J Psychiatry Suppl; 1989 May; (4):73-6. PubMed ID: 2605013
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormonal responses to dextroamphetamine in depressed and normal adolescents.
    Waterman GS; Ryan ND; Puig-Antich J; Meyer V; Ambrosini PJ; Rabinovich H; Stull S; Novacenko H; Williamson DE; Nelson B
    J Am Acad Child Adolesc Psychiatry; 1991 May; 30(3):415-22. PubMed ID: 2055877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple hormone responses to stimulation with dl-fenfluramine in patients with major depression before and after antidepressive treatment.
    Kasper S; Vieira A; Schmidt R; Richter P
    Pharmacopsychiatry; 1990 Mar; 23(2):76-84. PubMed ID: 2339181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responses to mCPP stimulation in depressed patients.
    Thakore JH
    Am J Psychiatry; 1995 Dec; 152(12):1833-4; author reply 1834-5. PubMed ID: 8526261
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome.
    Bearn J; Allain T; Coskeran P; Munro N; Butler J; McGregor A; Wessely S
    Biol Psychiatry; 1995 Feb; 37(4):245-52. PubMed ID: 7711161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine regulation of growth hormone secretion in major depressive disorder.
    Lesch KP; Laux G; Erb A; Pfüller H; Beckmann H
    Pharmacopsychiatry; 1988 Nov; 21(6):440-2. PubMed ID: 3149754
    [No Abstract]   [Full Text] [Related]  

  • 7. Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression.
    Thakore JH; Dinan TG
    Biol Psychiatry; 1995 Mar; 37(6):364-8. PubMed ID: 7772644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone, cortisol and prolactin responses to physical exercise: higher prolactin response in depressed patients.
    Kiive E; Maaroos J; Shlik J; Tõru I; Harro J
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):1007-13. PubMed ID: 15380861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Towards an attempt at biological differentiation of endogenous and exogenous depression: a study of beta-endorphins and other parameters (prolactin, growth hormone and dexamethasone repression test) in a cohort of ambulatory depressed patients].
    Gallart JM; Galard R; Catalan R; Arguello JM; Castellanos JM; Schwartz S
    Ann Med Psychol (Paris); 1988; 146(8):758-63. PubMed ID: 2977276
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of the placebo control condition in neuroendocrine challenge studies.
    Thompson PA; Maes M; Meltzer HY
    Psychiatry Res; 1994 Jun; 52(3):317-26. PubMed ID: 7991724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neuroendocrine response to fenfluramine in depressives and normal controls.
    Asnis GM; Eisenberg J; van Praag HM; Lemus CZ; Friedman JM; Miller AH
    Biol Psychiatry; 1988 May; 24(1):117-20. PubMed ID: 3370273
    [No Abstract]   [Full Text] [Related]  

  • 12. Hormonal responses to fenfluramine in depressive subtypes.
    Mitchell P; Smythe G; Parker G; Wilhelm K; Hickie I; Brodaty H; Boyce P
    Br J Psychiatry; 1990 Oct; 157():551-7. PubMed ID: 2131137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated cortisol concentrations and the diminished prolactin response to fenfluramine.
    Mitchell PB; Smythe GA
    Am J Psychiatry; 1992 Jun; 149(6):851-2. PubMed ID: 1590517
    [No Abstract]   [Full Text] [Related]  

  • 14. Responses to mCPP stimulation in depressed patients.
    Pitchot W; Ansseau M; Gonzalez Moreno A; Hansenne M
    Am J Psychiatry; 1995 Dec; 152(12):1834; author reply 1834-5. PubMed ID: 8526262
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of electroconvulsive treatment on monoamine metabolites, growth hormone, and prolactin in plasma.
    Linnoila M; Litovitz G; Scheinin M; Chang MD; Cutler NR
    Biol Psychiatry; 1984 Jan; 19(1):79-84. PubMed ID: 6200149
    [No Abstract]   [Full Text] [Related]  

  • 16. Interest of 5-hydroxytryptophan (5-HTP) as a neuroendocrine marker in depressive illness. A negative report.
    Ansseau M; Doumont A; Thiry D; Geenen V; Legros JJ
    Acta Psychiatr Belg; 1983; 83(1):50-6. PubMed ID: 6604395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Laboratory diagnosis of depressive disorders].
    Linkowski P
    Rev Med Brux; 1983 Apr; 4(4):229-33. PubMed ID: 6410481
    [No Abstract]   [Full Text] [Related]  

  • 18. Pre- and postsynaptic alpha-adrenergic effects of clonidine in major depressive disorder.
    Lesch KP; Laux G; Schulte HM; Erb A; Pfüller H; Beckmann H
    Pharmacopsychiatry; 1988 Nov; 21(6):430-1. PubMed ID: 2854278
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiendocrine assessment in the dexamethasone suppression test.
    Risch SC; Janowsky DS; Judd LL; Gillin C; Mott M; Rausch JL; Huey LY
    Psychopharmacol Bull; 1986; 22(3):913-6. PubMed ID: 3025914
    [No Abstract]   [Full Text] [Related]  

  • 20. Hormone response to 5-HTP.
    Meltzer HY; Tricou BJ; Robertson A; Lowy M
    Psychiatry Res; 1983 Oct; 10(2):151-2. PubMed ID: 6606814
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.